Colorectal Cancer Trial, Recruiting NCT07283575 Sponsor: Fudan University Condition: Colorectal Cancer
Back to Colorectal Cancer

Colorectal Cancer Trial, Recruiting

NCT07283575
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Adults aged 18 or older, of any gender
  • People who have been diagnosed with colorectal cancer (confirmed by a tissue sample) that has come back or spread to other parts of the body
  • People whose doctors consider them suitable to receive radiation therapy combined with standard chemotherapy, with or without a type of cancer medication that works with the immune system (called a PD-1 inhibitor)
  • People who are expected to live for more than 6 months
  • People (or their legal guardian or representative) who are willing to sign a consent form showing they understand and agree to take part in the study

Who may not be able to join:

  • People who had a blood transfusion during surgery or within 2 weeks before surgery
  • Women who are pregnant, breastfeeding, or capable of becoming pregnant and not using adequate contraception
  • People who have been diagnosed with another type of cancer in the past 5 years, except for certain skin cancers (non-melanoma) or cervical cancer in situ that have been fully cured
  • People who have brain tumours or cancer that has spread to the brain or central nervous system and is not well controlled, especially if there is significant pressure in the skull or related symptoms
  • People who have serious or poorly controlled health conditions, including: a significant heart problem within the past 6 months (such as a heart attack, heart failure, unstable chest pain, fluid around the heart, or irregular heartbeat); a confirmed serious neurological or psychiatric condition such as dementia or seizures; a severe or uncontrolled infection; or an active blood-clotting disorder with significant bleeding
  • People with significant loss of function in a major organ (confirm with trial site)
  • People whose doctor believes, for any other reason, that participation in this trial would not be appropriate

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 21 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
10 October 2025
Est. completion
10 October 2028

Where this trial is recruiting

🇨🇳 China

Primary endpoints

PFS

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov